Since that report, RAC has suggested multiple organ protection as well as anti-chemo accelerated aging could be in play.
The Triangle report either needs updating or investors need to consider the revised total addressable market if these claims are proven.
My main hope is that RAC share holders get to see fair value realised if clinical data supports these assertions.
Add to My Watchlist
What is My Watchlist?
